First-in-human Study of 7MW4911 in GI Cancer

Recruiting now · Phase 1/Phase 2

Conditions studied: GI Cancers

In brief

This is the first-in-human study of 7MW4911 in US patients, to investigate its prelimary safety and efficacy in patients with gastrointestinal cancers.

Key facts

Study ID

NCT07216560

Run by

Mabwell (Shanghai) Bioscience Co., Ltd.

People needed

200

Starts

2026-01-13

Expected to finish

2028-12-01

Last updated by the study team

2026-04-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 18 and above
• ECOG 0-1
• Life expectancy ≥ 3 months
• Advanced or metastatic gastrointestinal cancer that has progressed after standard of care.
• Disease progression after the most recent treatment regimen
• At least one measurable lesion according to RECIST v1.1
• Provision of archival tumor tissue or fresh biopsy.
• Adequte hematologic funciton, liver function and renal function.
• Comply with contraceptive requirements

You may not qualify if…

• Other concurrent malignancy in the recent 3 years except for adequately treated carcinoma in situ.
• Active, untreated or symptomatic CNS metastasis
• Effusions that require frequent drainage
• Patients with active autoimmune disease, except for type I diabetes, hypothyroidism and other autoimmune disease that does not require systemic treatment.
• Severe respiratory disease that required hospitalization in the last 28 days.
• Significant and uncontrolled cardiovascular disease or events in the 6 months prior to study drug administration
• Poorly controlled blood glucose with fasting blood glucose above 10mmol/L
• Recipient of allogeneic stem cell transplant or organ transplant
• Active HIV or hepatitis B/C infection. Infection requiring systemic IV in the 14 days prior to study drug administration.
• Experiencing toxicities from prior anti-cancer therapies that have not recovered to CTCAE grade 0-1, except for alopecia and endocrinopathies.
• Prohibited treatment and treatment that requires washout period
• Has received another Topo-I payload ADC, and/or another CDH17 targeting therapy.
• Received other cancer therapy within 5 half-lives or 21 days prior to study drug administration.
• Major surgeries within 28 days prior to study drug administration
• Investigational therapy within 28 days prior to study drug administration
• Systemic treatment with immunosuppressive agents within 28 days prior to first drug administration. Physiological dose of glucocorticoid, topical glucocorticoid are allowed.
• Use of strong CYP3A4 inhibitor or inducer
• Known hypersensitivity to 7MW4911 or components of the formulation
• Abuse of narcotic or psychoactive drugs
• Pregnant or breastfeeding women
• Other circumstances or conditions where the investigator judges to be unsuitable for study.

Where it is running

• Hematology Oncology Associates of the Treasure Coast — Port Saint Lucie, Florida, United States (enrolling)
• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
• START — Long Island City, New York, United States (enrolling)
• START Moutain Region — West Valley City, Utah, United States (enrolling)
• Fred Hutchinson Cancer Center — Seattle, Washington, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.